Together these results suggest a reduction of oocyte developmental competence and raise questions about the oocyte-specific action of AMPK in cases of metabolic disorders such as insulin resistance and polycystic ovary syndrome. This evidence concerns the gene PRKAA1 and polycystic ovary syndrome.